In:
The Journal of Immunology, The American Association of Immunologists, Vol. 186, No. 1_Supplement ( 2011-04-01), p. 48.13-48.13
Abstract:
IL17A is a cytokine mainly produced by Th17 cells. The function of the Th17 cell lineage in lung cancer remains to be elucidated. In our study we found increased expression of the Th17 transcription factors RORα4 and RORγt and the cytokine IL-17A in the lungs of patients with lung adenocarcinoma compared to healthy control tissue. In lung cancer tissues IL-17A inversely correlated with the Th1 specific factor T-bet. Targeting of IL-17A in a murine model of lung adenocarcinoma by intranasal application of anti IL17A antibodies resulted in reduction of lung tumor load and prolonged survival of wild-type mice. Studies in T-bet (-/-) mice revealed up-regulation of lung IL-23/IL-23-R and IL-17A/IL-17A-R in T cells infiltrating the tumor. Local anti-IL-17A antibodies treatment improved (50%) survival in treated T-bet (-/-) mice, reduced the number of IL-17R expressing lung CD4+ T cells, induced the number of natural killer cells and CD8+ T cells producing IFNγ compared to wild type littermates-bearing tumor and treated in the same way. These data might indicate that local anti IL-17A antibody therapy could be successful for the treatment of lung tumor also in the absence of T-bet.
Type of Medium:
Online Resource
ISSN:
0022-1767
,
1550-6606
DOI:
10.4049/jimmunol.186.Supp.48.13
Language:
English
Publisher:
The American Association of Immunologists
Publication Date:
2011
detail.hit.zdb_id:
1475085-5
